Deals In Depth: June/July 2013
In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.
You may also be interested in...
Medicare Payment Advisory Commission also considering reviving least costly alternative policy in some way, but remains relatively hesitant about changes to ASP+6%.
Answer 10 minutes of questions about what you want from our stories and be eligible to win a $100 gift card.
As Biden administration and MedPAC both work on ideas to overhaul Part B, marketers of physician-administered drugs (primarily for cancer, ophthalmology and rheumatological disorders) should prepare for a fight – but only if the broader ‘negotiation’ push fails.